Neoadjuvant combination therapy for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs before bladder removal surgery in people with muscle-invasive bladder cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have muscle-invasive bladder cancer that has not spread beyond the pelvis (stages T2-T4a, N0-N1, M0, or T1 with N1).
- You are scheduled to have your bladder removed (radical cystectomy).
- You are healthy enough to receive chemotherapy and immunotherapy as determined by your doctor.
- Your kidney, liver, and blood counts meet certain minimum levels.
- You have not had prior systemic treatment for muscle-invasive bladder cancer (prior treatment for non-muscle-invasive is allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to see if they can control muscle-invasive bladder cancer without needing to remove the bladder. It may be an option for people who want to try to preserve their bladder and avoid surgery or radiation.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
This trial tests a new combination of two drugs before bladder removal surgery for patients with HER2-positive muscle-invasive bladder cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.